GleamWall
中文EN

RAPP Rapport Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2012593 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-54.0%
TTM EPS YoY-39.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-33.3%
ROA-31.5%
ROIC (approx.)-45.9%
Asset turnover—

Leverage & solvency

Liabilities / assets6.5%
Debt / equity0.00x
Current ratio20.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$20.00M—$0$0$0—
R&D expense$34.32M$51.41M$32.72M$30.26M$22.28M$22.68M$19.57M$17.20M
SG&A expense$9.77M$9.39M$11.50M$8.25M$7.71M$6.82M$7.54M$6.32M
Operating income-$44.09M-$60.81M-$24.21M-$38.51M-$29.99M-$29.50M-$27.11M-$23.52M
Pretax income———————-$19.98M
Net income-$40.23M-$56.62M-$19.86M-$33.76M-$26.93M-$26.73M-$24.06M-$19.98M
EBITDA-$43.89M-$60.59M-$23.99M-$38.24M-$29.73M-$29.24M-$26.86M-$23.26M
EPS (basic)-0.84-1.19-0.42—-0.71-0.75-0.68—
EPS (diluted)-0.84-1.19-0.42—-0.71-0.75-0.68—
Weighted avg. shares (diluted)47.77M47.47M47.24M—37.93M35.44M35.27M—
Balance sheet
Cash & equivalents$74.75M$63.61M$78.06M$52.65M$251.36M$55.07M$57.60M$56.80M
Short-term investments$320.27M$372.46M$398.73M$437.89M$261.67M$205.38M$227.78M$248.47M
Receivables$171,000$293,000$58,000$0————
Current assets$407.38M$446.86M$484.69M$498.56M$520.66M$270.24M$290.97M$309.80M
PP&E, net$1.96M$2.34M$2.52M$2.98M$3.12M$3.17M$3.40M$3.53M
Total assets$418.56M$458.98M$497.60M$512.43M$535.32M$285.50M$302.05M$314.93M
Current liabilities$20.30M$28.42M$17.90M$19.05M$14.32M$11.88M$9.38M$8.77M
Total liabilities$27.37M$36.06M$26.09M$27.78M$23.71M$21.98M$16.22M$9.51M
Shareholders' equity$391.19M$422.93M$471.51M$484.65M$511.62M$263.51M$285.84M$305.43M
Shares outstanding48.09M47.96M47.81M47.77M47.65M36.50M36.50M36.58M
Cash flow statement
Operating cash flow-$41.63M-$41.45M-$13.06M-$24.70M-$17.46M-$25.07M-$20.24M-$14.45M
Capital expenditure$0$78,000$86,000$169,000$134,000$22,000$291,000$226,000
Free cash flow-$41.63M-$41.53M-$13.15M-$24.87M-$17.60M-$25.09M-$20.53M-$14.67M
Investing cash flow$51.06M$25.60M$37.94M-$174.32M-$56.78M$22.60M$21.03M$31.93M
Financing cash flow$1.71M$1.41M$531,000$311,000$270.53M-$63,000$5,000$7,000
Depreciation & amortization$198,000$212,000$227,000$265,000$256,000$252,000$244,000$260,000
Stock-based compensation$7.63M$7.20M$6.96M$5.69M$4.74M$4.39M$4.04M$3.21M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.